Live Breaking News & Updates on Antagonist Deucrictibant

Stay updated with breaking news from Antagonist deucrictibant. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Deucrictibant Data Highlighted in Multiple Presentations at the C1-Inhibitor Deficiency and Angioedema Workshop

ZUG, Switzerland, May 06, 2023 Pharvaris , a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent hereditary angioedema attacks, today announced. | May 6, 2023 ....

United States , United Kingdom , Anna Valerieva , Remys Peterson , Anne Lesage , Henriette Farkas , Brigitte Loenders , Marcus Maurer , Peng Lu , Marca Riedl , Globenewswire Inc , European Union , Early Development , Exchange Commission , Angioedema Workshop , Chief Medical Officer , Chief Early Development Officer , Antagonist Deucrictibant , Against Bradykinin Effects , Healthy Volunteers Predicts , Its Clinical Effects , Hereditary Angioedema Attacks , Topline Results , Mean Symptom Complex Severity , Treatment Outcome Score , Statement Regarding Forward Looking ,